AU2020277398B2 - Solid state forms - Google Patents

Solid state forms

Info

Publication number
AU2020277398B2
AU2020277398B2 AU2020277398A AU2020277398A AU2020277398B2 AU 2020277398 B2 AU2020277398 B2 AU 2020277398B2 AU 2020277398 A AU2020277398 A AU 2020277398A AU 2020277398 A AU2020277398 A AU 2020277398A AU 2020277398 B2 AU2020277398 B2 AU 2020277398B2
Authority
AU
Australia
Prior art keywords
compound
present disclosure
theta
degrees
peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020277398A
Other languages
English (en)
Other versions
AU2020277398A1 (en
Inventor
Prashant Agarwal
Mary Chaves
Ron C. Kelly
Stephan D. Parent
Darren Leonard REID
Roman SHIMANOVICH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU2020277398A1 publication Critical patent/AU2020277398A1/en
Priority to AU2026200455A priority Critical patent/AU2026200455A1/en
Application granted granted Critical
Publication of AU2020277398B2 publication Critical patent/AU2020277398B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
AU2020277398A 2019-05-21 2020-05-20 Solid state forms Active AU2020277398B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2026200455A AU2026200455A1 (en) 2019-05-21 2026-01-22 Solid state forms

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962851049P 2019-05-21 2019-05-21
US62/851,049 2019-05-21
PCT/US2020/033832 WO2020236948A1 (en) 2019-05-21 2020-05-20 Solid state forms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026200455A Division AU2026200455A1 (en) 2019-05-21 2026-01-22 Solid state forms

Publications (2)

Publication Number Publication Date
AU2020277398A1 AU2020277398A1 (en) 2021-12-09
AU2020277398B2 true AU2020277398B2 (en) 2026-01-29

Family

ID=71016701

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020277398A Active AU2020277398B2 (en) 2019-05-21 2020-05-20 Solid state forms
AU2026200455A Pending AU2026200455A1 (en) 2019-05-21 2026-01-22 Solid state forms

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2026200455A Pending AU2026200455A1 (en) 2019-05-21 2026-01-22 Solid state forms

Country Status (10)

Country Link
US (1) US12252486B2 (https=)
EP (1) EP3972972A1 (https=)
JP (2) JP2022532790A (https=)
AR (1) AR119741A1 (https=)
AU (2) AU2020277398B2 (https=)
CA (1) CA3140394A1 (https=)
MX (2) MX2021014235A (https=)
TW (1) TW202110836A (https=)
UY (1) UY38711A (https=)
WO (1) WO2020236948A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119183A2 (en) 2016-12-22 2018-06-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
EA201992781A1 (ru) 2017-05-22 2020-04-01 Эмджен Инк. Ингибиторы g12c kras и способы их применения
MA50077A (fr) 2017-09-08 2020-07-15 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
ES2995514T3 (en) 2018-05-04 2025-02-10 Amgen Inc Kras g12c inhibitors and methods of using the same
WO2019213516A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
US11932633B2 (en) 2018-05-07 2024-03-19 Mirati Therapeutics, Inc. KRas G12C inhibitors
EP3790886B1 (en) 2018-05-10 2024-06-26 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
ES2938987T3 (es) 2018-06-01 2023-04-18 Amgen Inc Inhibidores de KRAS G12c y métodos de uso de los mismos
US20190375749A1 (en) 2018-06-11 2019-12-12 Amgen Inc. Kras g12c inhibitors and methods of using the same
ES3060664T3 (en) 2018-06-12 2026-03-27 Amgen Inc Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
SMT202500028T1 (it) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Terapie combinate
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
WO2020055761A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
JP2022500385A (ja) 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
US11053226B2 (en) 2018-11-19 2021-07-06 Amgen Inc. KRAS G12C inhibitors and methods of using the same
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
CN113164418A (zh) 2018-12-05 2021-07-23 米拉蒂治疗股份有限公司 组合疗法
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
NZ782284A (en) 2019-05-21 2024-11-29 Amgen Inc Solid state forms
AU2020277398B2 (en) 2019-05-21 2026-01-29 Amgen Inc. Solid state forms
WO2021041671A1 (en) 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
CN114761012B (zh) 2019-09-24 2025-03-21 米拉蒂治疗股份有限公司 组合疗法
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
WO2021236920A1 (en) * 2020-05-20 2021-11-25 Teva Pharmaceuticals International Gmbh Solid state forms of amg-510 and process for preparation thereof
WO2021249563A1 (zh) * 2020-06-12 2021-12-16 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
WO2022056307A1 (en) 2020-09-11 2022-03-17 Mirati Therapeutics, Inc. Crystalline forms of a kras g12c inhibitor
HRP20251311T1 (hr) * 2020-11-26 2026-02-27 Shanghai Hansoh Biomedical Co., Ltd. Sol i kristalni oblik heterocikličkog derivata koji sadrži dušik, metoda njihove pripreme i njihova primjena
WO2022132200A1 (en) 2020-12-15 2022-06-23 Mirati Therapeutics, Inc. Azaquinazoline pan-kras inhibitors
EP4262803A4 (en) 2020-12-16 2025-03-12 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
WO2022246069A1 (en) 2021-05-19 2022-11-24 Teva Pharmaceuticals International Gmbh Process for preparation of sotorasib and solid state form thereof
CN114605406B (zh) * 2021-09-18 2023-05-26 都创(上海)医药开发有限公司 Amg510化合物的晶型及其制备方法和用途
CN115368358A (zh) * 2022-09-01 2022-11-22 浙江九洲药业股份有限公司 一种Sotorasib新晶型及其制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180334454A1 (en) * 2017-05-22 2018-11-22 Amgen Inc. Kras g12c inhibitors and methods of using the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201312059D0 (en) 2013-07-05 2013-08-21 Univ Leuven Kath Novel GAK modulators
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
AU2014331794C1 (en) 2013-10-10 2019-09-12 Araxes Pharma Llc Inhibitors of KRAS G12C
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
JP2018513853A (ja) 2015-04-10 2018-05-31 アラクセス ファーマ エルエルシー 置換キナゾリン化合物およびその使用方法
JP7039489B2 (ja) 2016-05-18 2022-03-22 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｃ阻害剤
WO2018119183A2 (en) 2016-12-22 2018-06-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
MA50077A (fr) 2017-09-08 2020-07-15 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
WO2019213516A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
AU2020277398B2 (en) 2019-05-21 2026-01-29 Amgen Inc. Solid state forms
NZ782284A (en) 2019-05-21 2024-11-29 Amgen Inc Solid state forms
WO2021097207A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
JP2023501528A (ja) 2019-11-14 2023-01-18 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の改善された合成

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180334454A1 (en) * 2017-05-22 2018-11-22 Amgen Inc. Kras g12c inhibitors and methods of using the same

Also Published As

Publication number Publication date
TW202110836A (zh) 2021-03-16
MX2025010774A (es) 2025-10-01
WO2020236948A1 (en) 2020-11-26
US20220235045A1 (en) 2022-07-28
JP2022532790A (ja) 2022-07-19
US12252486B2 (en) 2025-03-18
AU2020277398A1 (en) 2021-12-09
MX2021014235A (es) 2022-03-11
AR119741A1 (es) 2022-01-05
AU2026200455A1 (en) 2026-02-12
JP2025131597A (ja) 2025-09-09
CA3140394A1 (en) 2020-11-26
UY38711A (es) 2020-11-30
EP3972972A1 (en) 2022-03-30

Similar Documents

Publication Publication Date Title
AU2020277398B2 (en) Solid state forms
US12415806B1 (en) Solid state forms
EP2542548A1 (en) Process for preparation of polymorphic form and new polymorphic form of imatinib mesylate isolated in that process
CN115413277B (zh) 吡嗪取代的烟酰胺的固体形式及其制备和用途
HK40116757A (zh) 固态形式
HK40063209A (en) Solid state forms
HK40063209B (zh) 固态形式
EA052301B1 (ru) Твердые формы
EA047965B1 (ru) Твердые формы
BR122024008690A2 (pt) Compostos de formas amorfas, composição farmacêutica comprendendo os mesmos e uso destes para tratamento de câncer com uma mutação kras g12c